leisure time -WSS

leisure time

author：focus 2025-09-03 07:37:41 - browse：75

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Morphosys mixed study results for blood cancer drug

WSS

In key trial, Verve's treatment lowers cholesterol levels in patients

The painfully weak evidence on taking collagen to treat arthritis

Judge rejects Trump's counterclaim against E. Jean Carroll

Anthos stroke drug appears safer than common blood thinner

Choosing scientific sides in the fight against Alzheimer's

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

hotspot

leisure time

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Surge of respiratory disease in China has likely explanation

New air purifier tech could be key to improving indoor air quality

More regulation could be coming for drug ads

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Weight loss drug costs may need more research, senator suggests

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC launches VaccineFinder tool to locate Covid

What does generative AI mean for health care? We asked experts

CRISPR pioneers react to Casgevy, first gene

hotspot

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Surge of respiratory disease in China has likely explanation

Gain of function research would be limited under House proposal

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Congress must reauthorize a committee to support older Americans

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

explore

leisure time

focus

leisure time